Overview The US market currently has 1 approved drug under the name Ocrevus (generic name: Ocrelizumab), which represents a significant therapeutic option for multiple sclerosis treatment. Developed by Genentech, Inc. and Biogen Idec Ltd., Ocrevus was approved in 2017 and has shown strong clinical efficacy in both relapsing and primary progressive forms of multiple sclerosis. The drug operates through a unique mechanism targeting CD20-expressing B-cells, leading to B-cell depletion primarily through antibody-dependent cellular cytolysis and complement-mediated lysis. With patent protection extending to 2028 through a Patent Term Extension (PTE) and a breakthrough therapy designation for primary progressive multiple sclerosis, Ocrevus maintains a strong market position with limited biosimilar competition at present. Detailed Description Drug Approval…
Author: Eileen
Overview Entresto (Sacubitril/Valsartan) represents a significant advancement in the heart failure treatment market in the USA. The total number of approved drugs in this therapeutic area is 1, highlighting Entresto’s unique position as a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI). Developed by Novartis, Entresto has demonstrated substantial clinical benefits in reducing cardiovascular death and heart failure hospitalizations. The drug maintains strong patent protection through 2037 for certain aspects, with initial approvals dating back to 2015. With its novel mechanism combining AT1R antagonism and enkephalinase inhibition, Entresto addresses a critical unmet need in the management of heart failure with reduced ejection fraction. Detailed Description Drug Information Entresto (Sacubitril/Valsartan) was developed by Novartis Pharma AG and is approved in the USA…
Overview Prolia (Denosumab) is an established biologic in the US market, with 1 approved drug available. Developed by Amgen, Inc., it was first approved in 2010 and has maintained a significant market presence. As a RANKL inhibitor, Prolia has shown effectiveness in treating osteoporosis and related bone disorders. The drug has attracted considerable interest from competitors, with 32 biosimilars in development, highlighting the market’s attractiveness. Prolia’s patent portfolio is extensive, with numerous patents extending beyond 2030, providing Amgen with significant market protection for this valuable asset. Detailed Description Drug Information Prolia (Denosumab) was developed by Amgen, Inc. and received FDA approval in the United States on June 1, 2010. Bio-similars There are 32 bio-similars,…
Overview Pomalyst (pomalidomide) represents a significant treatment option in the US oncology market, with only 1 approved drug containing pomalidomide. Originally developed by Celgene Corporation (now part of Bristol Myers Squibb), Pomalyst was first approved in 2013 and has become an important therapy for multiple myeloma and Kaposi sarcoma. The drug acts as a CRBN modulator and IKZF1/IKZF3 degrader, offering a unique mechanism of action. The market for this specialty oncology product continues to grow as its indications expand and its use in combination therapies increases. Detailed Description Drug Information Pomalyst (pomalidomide) was developed by Celgene Corporation and launched in the USA in 2013. There are no bio-similars identified for this product. Special Review Structure…
Overview Keytruda (pembrolizumab) is a leading immunotherapy drug in the US market, with 1 approved drug and 25 biosimilar products in development, demonstrating significant market interest. Developed by Merck & Co. (Merck Sharp & Dohme LLC), Keytruda has become a cornerstone of cancer immunotherapy with numerous approvals across multiple indications, including melanoma, non-small cell lung cancer, head and neck cancer, and many others. The drug has received multiple special designations including Breakthrough Therapy, Priority Review, Orphan Drug, and Accelerated Approval designations for various indications, highlighting its clinical significance. Drug Approval Keytruda was developed by Merck Sharp & Dohme LLC and launched in the USA in 2014. Special Review Note: Table truncated…
Overview The US market currently has 1 approved drug containing lenalidomide. Lenalidomide, marketed under the brand name Revlimid, was originally developed by Celgene Corporation (now part of Bristol Myers Squibb) and has become a cornerstone therapy for multiple hematological malignancies. The drug has received multiple orphan drug designations in the US for various indications including Multiple Myeloma (2001), Myelodysplastic Syndromes (2004), Mantle-Cell Lymphoma (2009), Follicular Lymphoma (2013), and Marginal Zone B-Cell Lymphoma (2017), highlighting its significant therapeutic value in treating rare diseases. The drug’s market performance has been substantial due to its efficacy across multiple indications and its use in combination therapies, particularly with dexamethasone and rituximab, which have shown enhanced therapeutic effects. Detailed Description Drug Information Lenalidomide was developed…
Overview Levothyroxine Sodium, marketed as Euthyrox in many countries, is one of the most widely prescribed medications in the US market. The US market has 1 approved drug for Levothyroxine Sodium, with numerous formulations, strengths, and manufacturers. This medication is primarily used for the treatment of hypothyroidism, hyperpituitarism, myxedema coma, and other thyroid-related conditions. The drug has been available for decades and has a mature market with multiple generic versions available. Despite being a well-established drug, it maintains a significant market presence due to the chronic nature of hypothyroidism requiring lifelong treatment. Detailed Description Drug Information Levothyroxine Sodium was originally developed…
Overview The US market has 1 approved drug for Fexofenadine Hydrochloride, marketed as Allegra. Originally developed by Sanofi, Inc., Allegra is a widely used antihistamine for the treatment of allergic rhinitis and chronic urticaria. The drug has been available in the US market since the 1990s and is currently marketed in various formulations. Most of the core patents protecting this drug have expired, creating significant opportunities for generic competition in the market. Detailed Description Drug Information Fexofenadine Hydrochloride (Allegra) was originally developed by Sanofi, Inc. and has been approved in the USA in multiple formulations: Structure Patent Statement Information There are patent statements for Allegra in the US: Trade NameSubmission DateAllegraPre-MMA Additionally,…
Overview Acetaminophen (known as Paracetamol internationally) is a widely established analgesic and antipyretic medication in the US market. There is currently 1 drug approved in the USA containing acetaminophen as the active ingredient, available in various formulations including tablets, extended-release tablets, suppositories, oral solutions, and intravenous injections. Acetaminophen is primarily used for the treatment of pain, fever, and headache. The drug has been on the market for decades and is available in both prescription and over-the-counter formulations, making it one of the most commonly used medications in the United States. Drug Approval Acetaminophen was developed by multiple pharmaceutical companies and has been available in the USA since at least…
Overview The US market has 1 drug approved as L-methylfolate, known by its chemical name Levomefolate calcium. Originally developed by Merck & Co., Inc., this compound is primarily used as a dietary supplement and also has applications in treating Angelman Syndrome. The drug has received orphan drug designation for Megaloblastic Anemia, highlighting its importance in treating specific rare conditions. L-methylfolate represents an important option in the folate supplement market, with its bioavailable form of folate being particularly valuable for individuals with genetic variations affecting folate metabolism, such as those with MTHFR gene polymorphisms. Detailed Description Drug Approval of L-Methylfolate Levomefolate calcium was originally developed by Merck & Co., Inc. and has…